News

Advanced Search

Securities Investigation: Against Ampio Pharmaceuticals, Inc.

DATE: August 31, 2022

AMPIO PHARMACEUTICALS, INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against Ampio Pharmaceuticals, Inc. (NYSE: AMPE); Lead Plaintiff Deadline is October 17, 2022

PHILADELPHIA, August 31, 2022Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) between December 29, 2020 and August 3, 2022 (the “Class Period”).

If you purchased the securities of Ampio during the Class Period, would like to discuss Berger Montague’s investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at [email protected] or (215) 875-3015, or Michael Dell’Angelo at [email protected] or (215) 875-3080 or visit: https://investigations.bergermontague.com/ampio-pharmaceuticals-inc/

The action arises out of the Company’s misstatements regarding the ability of Ampion, its lead product, to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (“OAK”). Beginning in 2010 until approximately March 2022, Ampio conducted numerous clinical trials and analyses to determine Ampion’s efficacy.

According to a recently filed complaint, Ampio, a pharmaceutical company developing Ampion to treat inflammatory conditions, represented that Ampion had demonstrated statistically significant decrease in pain associated with osteoarthritis of the knee.

On May 16, 2022, the Company announced it had formed a special committee to conduct internal investigations focusing on the statistical analysis of Ampio’s AP-013 clinical trial and unauthorized provision of Ampion, which had not yet been approved by the U.S. Food and Drug Administration.

Then, on August 3, 2022, Ampio revealed that “senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-103 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function, and that these persons did not fully report the results of the AP-103 trial and the timing of unblinding of data from the AP-103 trial.”

Whistleblowers: Anyone with non-public information regarding Ampio is encouraged to confidentially assist Berger Montague’s investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

Request A Free Consultation